ModifiedAmeriHealth CaritasPolicy CCP.1323

Dermabrasion and chemical peel

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1323 alerts

Get alerted when Policy CCP.1323 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines AmeriHealth Caritas coverage stance and clinical criteria for dermabrasion and chemical peel procedures, primarily for treatment of pre-cancerous actinic keratosis and other pre-malignant skin conditions; intended for providers and coverage reviewers.

Policy Summary

PayerAmeriHealth Caritas

PolicyDermabrasion and chemical peel

Policy CodePolicy CCP.1323

Change TypeEvidence addition & organization

Effective DateAug 1, 2025

Last ReviewAug 1, 2025

Next Review DateDec 1, 202639d

Key ActionObtain prior authorization and document that conventional therapies (e.g., 5‑fluorouracil, imiquimod, cryotherapy) were ineffective, contraindicated, or refused when requesting coverage for dermabrasion or chemical peel for actinic keratosis.

SourceLink

POLICY UPDATE CHANGES

Findings section was reorganized by theme and evidence type, and a new systematic review and guideline were added.

A new systematic review (Meretsky, 2024) and a new guideline (Ceryn, 2025) were added to the evidence base.

actinic keratosisprimary covered indication

cosmetic usesconsidered investigational

listedexplicit contraindications

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedAmeriHealth CaritasPolicy CCP.1323

Dermabrasion and chemical peel

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1323 alerts

Get alerted when Policy CCP.1323 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmeriHealth Caritas

PolicyDermabrasion and chemical peel

Policy CodePolicy CCP.1323

Change TypeEvidence addition & organization

Effective DateAug 1, 2025

Last ReviewAug 1, 2025

Next Review DateDec 1, 202639d

SourceLink

POLICY UPDATE CHANGES

Findings section was reorganized by theme and evidence type, and a new systematic review and guideline were added.

A new systematic review (Meretsky, 2024) and a new guideline (Ceryn, 2025) were added to the evidence base.

actinic keratosisprimary covered indication

cosmetic usesconsidered investigational

listedexplicit contraindications

limitedevidence limited

179 RCTsnetwork meta-analysis

2017–2025policy update history

Coverage Criteria

Initial Therapy Coverage

Covered when ALL of the following are met

Primary Indication: Procedure is for pre-cancerous actinic keratosis or other pre-malignant skin conditions

Supported by guideline references: dermabrasion and chemical peels may be medically necessary for removal of actinic keratosis or other pre-malignant lesions.

Conventional therapy failure/contraindication/refusal: Conventional methods (e.g., 5-fluorouracil, imiquimod, cryotherapy) are not effective due to large number of lesions, are contraindicated, or have been refused by the patient

Per NCCN, AAD, and other guideline statements cited in policy

Use of dermabrasion and chemical peels for cosmetic purposes is explicitly noted as not medically necessary and is considered investigational/not clinically proven. The policy also excludes these modalities for the treatment of established carcinoma; clinical guidelines recommend surgical excision as the primary treatment for basal cell carcinoma and cutaneous squamous cell carcinoma, and chemical peels or conventional dermabrasion are not listed as treatment options once carcinoma is diagnosed.

The evidence base for dermabrasion and chemical peels is limited by a paucity of controlled trials and an absence of professional guidelines that specifically address these procedures and their comparative effectiveness. This limitation reduces the ability to make definitive statements about relative treatment efficacy across indications and supports a cautious coverage posture where strong evidence is lacking.

Procedures performed for cosmetic purposes are considered investigational and therefore not medically necessary. Because these uses lack clinical proof of benefit, coverage for cosmetic indications is not provided under this policy.

Provider Actions and Authorization

Prior Authorization

Prior authorization may be required when first‑line therapies fail, are contraindicated, or refused

Coverage is allowed for dermabrasion or chemical peel to treat actinic keratosis when conventional methods (e.g., 5‑fluorouracil, imiquimod, or cryotherapy) are ineffective because of extensive lesion burden, are contraindicated, or have been refused by the patient; prior authorization may be required per plan rules to document these conditions.

Conventional methods named explicitly: 5‑fluorouracil, imiquimod, cryotherapy.

Prior Authorization

Prior authorization governance may evolve with policy updates

Policy history documents iterative reference updates and multiple coverage modifications from 2017 through 2025, indicating that prior authorization governance and implementation may be subject to change per the payer's current policy version.

Policy update timeline: 7/2017 initial review; references and coverage modified repeatedly through 8/2025.

Definitions and Procedure Types

Superficial peels — definition and healing

DefinitionSuperficial peels gently exfoliate the outer layer of skin (epidermis).

Typical agentsOften low-strength alpha- or beta-hydroxy acids (as described in topical superficial peel practice).

Healing timeframeTypically 1–7 days to heal.

Medium peels — agents and healing

DefinitionMedium peels remove damaged skin cells in the outer and middle layers of skin (epidermis and superficial dermis).

Typical agentsGlycolic acid or trichloroacetic acid (TCA).

Healing timeframe

Background

Dermabrasion is a mechanical resurfacing technique that planes the skin by removing the epidermis and superficial dermis with a rotating brush or diamond fraise. Microdermabrasion differs in scope and invasiveness: it is a non‑surgical exfoliation limited primarily to the stratum corneum using abrasive crystals or device tips and is considerably less invasive than conventional dermabrasion.

Policy Summary

PayerAmeriHealth Caritas

PolicyDermabrasion and chemical peel

Policy CodePolicy CCP.1323

Change TypeEvidence addition & organization

Effective DateAug 1, 2025

Last ReviewAug 1, 2025

Next Review DateDec 1, 202639d

SourceLink

On This Page

Step Therapy

Expect topical therapy or cryosurgery as first‑line before resurfacing procedures

Clinical guidance designates topical agents and cryosurgery as primary (first‑line) treatments for actinic keratosis; dermabrasion and chemical peels are described as alternative options when first‑line therapies are impractical or unsuccessful.

American Academy of Dermatology recommends topical agents and cryosurgery as primary treatments.
NCCN and guideline text support dermabrasion/chemical peels as alternatives when first‑line therapies are contraindicated, ineffective, or refused.

Step Therapy

No explicit step‑therapy mandate in this policy

This policy section does not impose a formal step‑therapy sequence specifying mandatory prior steps; no explicit step‑therapy requirement is stated in the document.

Documentation Required

Document failure, contraindication, or refusal of conventional therapies

When requesting dermabrasion or chemical peel for actinic keratosis, document that conventional methods (for example 5‑fluorouracil, imiquimod, or cryotherapy) were ineffective, contraindicated, or refused by the patient to support medical necessity.

Document which conventional therapy was tried and the reason for failure, contraindication, or refusal.
Include clinical details such as extent of lesions (e.g., large number or field cancerization) that justify alternative therapy.

Note

Reported literature search methods and sources

The policy reports its literature search strategy and sources: searches of PubMed and databases of the Cochrane Library, CRD (UK NHS Centre for Reviews and Dissemination), AHRQ, and CMS were performed with terms including 'dermabrasion (MeSH)', 'chemexfoliation (MeSH)', 'chemical peel', 'actinic keratosis', and related terms.

Search date: July 21, 2025.
Databases: PubMed, Cochrane Library, CRD, AHRQ, CMS; specified MeSH and keyword terms listed in the references section.

Denial Risk

High denial risk for cosmetic‑purpose procedures

Procedures performed primarily for cosmetic purposes are considered investigational/not medically necessary under this policy and are therefore subject to denial.

Cosmetic indications for dermabrasion or chemical peels are explicitly listed as investigational/not clinically proven and not medically necessary.

Denial Risk

Coverage uncertainty due to limited high‑quality evidence

The document notes limited high‑quality controlled trial evidence and a lack of professional guidelines specific to dermabrasion and chemical peels; this evidence insufficiency may lead to coverage uncertainty or denial for indications lacking robust support.

The policy states relative efficacy is hampered by lack of controlled trials and guideline specificity.
New systematic review and guideline additions were made in 2024–2025, reflecting evolving evidence.

Typically 7–14 days to heal.

Deep peels — agents, depth, and healing

DefinitionDeep peels penetrate into the middle layer of skin and remove damaged cells beyond the superficial dermis.

Typical agentsTrichloroacetic acid (high concentration) or phenol.

Healing timeframeTypically 14–21 days to heal.

Dermabrasion — mechanical resurfacing

Procedure descriptionDermabrasion uses a hand-held, rapidly rotating wire brush or diamond fraise (steel wheel) to plane or sand the skin, removing the epidermis and superficial dermis.

Use contextUsed for acne and injury-induced scarring, sun-damaged and wrinkled skin, rhinophyma, and precancerous skin lesions.

Comparative noteTraditional dermabrasion is used less often due to availability of less invasive procedures.

Microdermabrasion — non-surgical exfoliation

DefinitionMicrodermabrasion is a less invasive, non-surgical exfoliation that removes the top layer of skin (stratum corneum) by blowing abrasive crystals or using devices.

TechniqueOften uses aluminum oxide crystals or other abrasive substances delivered by a hand-held device; may also use laser resurfacing as a less invasive alternative.

Clinical roleLess invasive than dermabrasion and used for superficial exfoliation rather than removing superficial dermis.

Chemical peels — brief definition

Short definitionChemical peels apply a solution to the skin that causes controlled exfoliation and peeling to improve skin texture and treat surface lesions.

ExamplesIncludes salicylic or mandelic acid treatments (noted in acne-related evidence).

Evidence noteNetwork meta-analysis found chemical peels (including salicylic/mandelic) among effective options for mild–moderate acne, but with high uncertainty.

Large actinic keratoses (>1 cm) — SCC risk feature

AssociationLarge actinic keratoses (>1 cm) have been identified as a feature associated with increased risk of progression to squamous cell carcinoma.

Clinical implicationPresence of large AKs supports treating lesions to prevent malignant progression.